Helix Acquisition III ^{Filed Terms, Nasdaq: HLXC}

We are a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Consistent with our business strategy, we expect to identify companies that have compelling growth potential and a combination of the following characteristics. We will seek to acquire companies or assets with a significant share of the following characteristics: rigorous science that includes a unique insight or a novel approach coupled to targets with clear, simple therapeutic rationale; compelling data indicating a drug candidate or platform is likely to generate a differentiated therapeutic for patients suffering from serious disease and with unmet need; nimble critical path to generate data that will advance one or more drug candidates through research, clinical, or regulatory milestones and value step-ups; the right management team with requisite experience and skills to develop and commercialize the most compelling drug candidates and that will benefit from our capital, advice, and network; an attractive valuation that traces to being overlooked as too early.